Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2016
Accounting Standards: International Financial Reporting Standards (IFRS)
Currency: Danish Kroner (DKK)
Novo Nordisk is a global healthcare company and a world leader in diabetes care, with additional leading positions in haemophilia care, growth hormone therapy, and obesity treatment. The company operates in two segments: diabetes and obesity care (approx. 80% of sales) and biopharmaceuticals. Headquartered in Denmark, it employs approximately 42,500 people across 75 countries.
Key Financial Metrics (2016)
| Metric | 2016 (DKK Millions) | 2015 (DKK Millions) |
|---|---|---|
| Net Sales | 111,780 | 107,927 |
| Operating Profit | 48,432 | 49,444 |
| Net Profit | 37,925 | 34,860 |
| Earnings Per Share (Basic) | 14.99 | 13.56 |
| Free Cash Flow | 39,991 | 34,222 |
| Net Cash from Operating Activities | 48,314 | 38,287 |
| Total Assets | 97,539 | 91,799 |
| Net Assets (Equity) | 45,269 | 46,969 |
| Capital Expenditure | 7,100 | 5,200 |
| Dividend Per Share | 7.60 | 6.40 |
Debt and Liquidity: No long-term loans were outstanding as of December 31, 2016. Current debt was minimal. Financial resources (cash, bonds, and undrawn credit facilities) totaled DKK 28,648 million. The company maintains a strong liquidity position, financing investments primarily through operating cash flow.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 3.6% to DKK 111.8 billion, driven by volume growth and new product launches, partially offset by currency fluctuations and pricing pressures.
- Profitability: Operating profit decreased slightly by 2.0% to DKK 48.4 billion, while Net Profit increased by 8.8% to DKK 37.9 billion, aided by a lower effective tax rate and favorable financial items.
- Product Performance:
- Tresiba (Insulin Degludec): Achieved 5.5% market share in the US basal insulin market and 39% in Japan.
- NovoLog/NovoRapid: Sales declined slightly (DKK 19.9B vs DKK 20.7B in 2015) due to patent expirations and competition.
- Vagifem: Sales declined (DKK 3.0B vs DKK 3.2B) following the loss of exclusivity in the US in October 2016.
- Norditropin: Sales increased (DKK 8.8B vs DKK 7.8B), boosted by a non-recurring positive rebate adjustment in the US Medicaid segment.
- Capital Allocation: The company completed a DKK 15 billion share repurchase program in January 2017 and announced a new DKK 16 billion program in February 2017. Dividends increased by 19% to DKK 7.60 per share.
Guidance, Outlook, and Risks
Outlook 2017:
- Capital Expenditure: Expected to be around DKK 10.0 billion, focused on expanding capacity for diabetes APIs and biopharmaceuticals.
- Pricing Environment: Average prices in the US after rebates are expected to be moderately lower in 2017 due to the launch of biosimilar glargine and formulary negotiations.
- R&D Spend: Expected to remain at 12-14% of sales.
- Key Launches: Xultophy (IDegLira) planned for US launch in H1 2017.
Risks and Contingencies:
- Patent Expirations: Key products like NovoLog, NovoMix, and Prandin face patent expirations, though formulation patents provide some protection. Biosimilar competition is a growing risk, particularly in China and the US.
- Regulatory and Pricing Pressure: Continued pressure from payers (PBMs, government) to reduce costs and increase rebates, especially in the US.
- Geopolitical: The company conducts business in Iran, Syria, and Sudan. Revenue from Iran-related transactions was under DKK 850 million in 2016. The company is subject to US sanctions laws regarding these activities.
- Legal: A class action lawsuit filed in January 2017 regarding insulin pricing was voluntarily dismissed and re-filed in New Jersey.
Investor Verification Checklist
- Patent Protection Status: Verify the remaining duration of formulation patents for key insulin products (NovoLog, NovoMix) and the timeline for biosimilar approvals in major markets (US, EU, Japan).
- US Pricing Trends: Monitor the impact of the biosimilar glargine launch and PBM negotiations on net sales and margins in the US market for 2017.
- Iran Operations: Review the specific nature of transactions with Government of Iran (GOI) entities to ensure compliance with evolving US sanctions regulations.
- Share Repurchase Execution: Track the execution of the new DKK 16 billion share repurchase program announced in February 2017.
- Product Pipeline: Assess the regulatory progress of oral semaglutide (PIONEER program) and the cardiovascular outcome trial for Tresiba (DEVOTE).